Impurities in Oligonucleotide Drug Substances and Drug Products

被引：78

作者：

Capaldi, Daniel ^{[1
]}

Teasdale, Andy ^{[2
]}

Henry, Scott ^{[1
]}

Akhtar, Nadim ^{[2
]}

den Besten, Cathaline ^{[3
]}

Gao-Sheridan, Samantha ^{[4
]}

Kretschmer, Matthias ^{[4
]}

Sharpe, Neal ^{[5
]}

Andrews, Ben ^{[6
]}

Burm, Brigitte ^{[7
]}

Foy, Jeffrey ^{[8
]}

机构：

[1] Ionis Pharmaceut Inc, 2855 Gazelle Court, Carlsbad, CA 92010 USA

[2] AstraZeneca UK Ltd, Macclesfield, Cheshire, England

[3] ProQR Therapeut NV, Leiden, Netherlands

[4] Alnylam Pharmaceut Inc, Cambridge, MA USA

[5] Anavex Life Sci Corp, New York, NY USA

[6] GlaxoSmithKline, Stevenage, Herts, England

[7] ISA Therapeut, Leiden, Netherlands

[8] Celgene Corp, Summit, NJ USA

来源：

NUCLEIC ACID THERAPEUTICS | 2017年 / 27卷 / 06期

关键词：

oligonucleotides; impurities; identification; qualification; PERFORMANCE LIQUID-CHROMATOGRAPHY; CAPILLARY GEL-ELECTROPHORESIS; IONIZATION MASS-SPECTROMETRY; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; INTERFERING RNA; NUCLEIC-ACIDS; THERAPEUTICS; DNA; RECOMMENDATIONS; OLIGODEOXYNUCLEOTIDES;

D O I：

10.1089/nat.2017.0691

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This white paper, which is the 10th in a series intended to address issues associated with the development of therapeutic oligonucleotides, examines the subject of product-related impurities. The authors consider chemistry and safety aspects and advance arguments in favor of platform approaches to impurity identification and qualification. Reporting, identification, and qualification thresholds suitable for product-related impurities of therapeutic oligonucleotides are proposed.

引用

页码：309 / 322

页数：14

共 50 条

[31] A Study of Nitrosamine Impurities and Regulations Governing their Presence in Drug Products
Nori, Lakshmi Prasanthi
Rehana, Sheik
Penamacha, Anusha
Somalanka, Bhanu Mounika
Raju, K. Venkateswara
INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2023, 13 (04) : 680 - 687
[32] Impurities in Active Pharmaceutical Ingredients and Drug Products: A Critical Review
Cordeiro, Cleydson Finotti
Franco, Lucas Lopardi
Carvalho, Diogo Teixeira
Bonfilio, Rudy
CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY, 2024,
[33] Quantification of impurities in commercial drug products containing montelukast and evaluation of the impurities' cytotoxic effects
Emerce, Esra
Cok, Ismet
Degim, Ismail Tuncer
TOXICOLOGY LETTERS, 2013, 221 : S95 - S95
[34] Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances
Humfrey, Charles D. N.
TOXICOLOGICAL SCIENCES, 2007, 100 (01) : 24 - 28
[35] RELATED SUBSTANCES BY HPLC METHOD FOR THE DETECTION AND EVALUATION OF IMPURITIES IN EZETIMIBE DRUG MATERIAL
Rapeti, Durgababu
Reddy, Gudibanda Chandra Sekhar
Narayanarao, Kapavarapu Maruthi Venkata
Shyamala, Pulipaka
Krishna, Rallabhandi Murali
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2021, 12 (01): : 217 - 225
[36] Regulatory Expectations Towards Genotoxic Impurities in Drug Substances: DMF and ASMF Perspective
Raman, Nanduri V. V. S. S.
Prasad, Adapa V. S. S.
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2014, 18 (07) : 834 - 835
[37] Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances
Zhang, Jinhui
Selaya, Susan Daniela
Shakleya, Diaa
Mohammad, Adil
Faustino, Patrick J.
JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 112 (05) : 1246 - 1254
[38] Approaches to Assessment, Testing Decisions, and Analytical Determination of Genotoxic Impurities in Drug Substances
Pierson, Duane A.
Olsen, Bernard A.
Robbins, Avid K.
DeVries, Keith M.
Varie, David L.
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2009, 13 (02) : 285 - 291
[39] Role of drug impurities in immunogenicity of substandard drug
Zdziarski, P
IMMUNOLOGY 2004: AUTOIMMUNITY, GENETIC AND DEGENERATIVE DISORDERS, MALIGNANCIES, AND TRANSPLANTATION, 2004, : 331 - 336
[40] Standards for drug impurities
不详
TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2010, 29 (08) : X - XI

← 1 2 3 4 5 →